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ㅋ
Patients that do not respond satisfactorily to standard proton pump inhibitor (PPI) treatment have become the most common 
presentation of gastro-esophageal reflux disease (GERD) in third referral gastrointestinal practices. The causes of refractory 
GERD include lack of compliance with treatment, residual acid reflux and weakly acidic reflux, esophageal hypersensitivity and 
persistent symptoms not associated with reflux. A role for weakly acidic reflux in symptom generation has been proposed since 
the availability of impedance-pH monitoring. The possible mechanisms by which persistent weakly acidic reflux might contri-
bute to persistent symptoms in patients under PPI treatment may include esophageal distension by increased reflux volume, 
persistent impaired mucosal integrity (ie, dilation of intercellular spaces) and/or esophageal hypersensitivity to weakly acidic re-
flux events. To establish a definite role of weakly acidic reflux in refractory GERD, outcome studies targeting this type of reflux 
are still lacking. Treatment strategies to reduce the number or effect of weakly acidic reflux could involve drugs that decrease 
transient lower esophageal sphincter relaxations (ie, baclofen or similar), improve oesophageal mucosa resistance or visceral 
pain modulators. Finally, anti-reflux surgery can be considered, only if a clear symptom-weakly acidic reflux association was 
demonstrated.
(J Neurogastroenterol Motil 2010;16:258-264)
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Introduction
Gastro-esophageal reflux disease (GERD) is a chronic dis-
order and remains the most common gastrointestinal-related di-
agnosis given on office visits.
1 The introduction of proton pump 
inhibitors (PPIs) has improved the esophageal mucosal healing 
and symptom control, however reports on PPI therapeutic failure 
in GERD patients have increased during the last years. It is esti-
mated that 10%-40% of patients fail to respond symptomatically, 
either partially or completely, to a standard dose PPI once 
daily.
2-4 Of these patients, the majority will continue to have 
symptoms even with higher doses of PPIs.
5,6
Therapy-resistant patients have become the most common 
presentation of GERD in third referral gastrointestinal practices. 
As GERD is the most expensive digestive disease, PPI failure 
contributes to the increased cost, due to repeated utilization of 
healthcare resources such as clinic visits, diagnostic tests and pre-
scription medications.
7,8
Patients with non-erosive reflux disease (NERD) have lower Weakly Acidic Reflux and PPI
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response rates to acid suppressive therapy than those who have 
erosive esophagitis.
9 Pooled symptomatic response rate to PPIs 
once daily at 4 weeks is only 37% for patients with NERD versus 
56% for patients with erosive esophagitis.
10,11 Moreover, sympto-
matic response to PPIs in patients with NERD is correlated with 
the extent of esophageal acid exposure. The patients with esoph-
ageal acid exposure within the normal range have the lowest re-
sponse rate to PPIs once daily.
12
There is no consensus definition of refractory GERD. Most 
investigators suggest that only patients, who experience partial or 
lack of response to PPIs twice daily, should be considered as PPI 
failure.
13,14 However, there is no GERD-related indication or 
re-imbursement policies for PPIs twice daily and, therefore, most 
studies on refractory GERD only include patients that remain 
symptomatic with PPI once daily.
In many cases it is unlikely that the patients’ persistent symp-
toms are due to gastro-esophageal reflux and a carefully taken 
history would reveal an alternative diagnosis.
15 Recent studies 
performed with esophageal pH-impedance monitoring have 
shown that up to 63% of refractory GERD patients report symp-
toms that cannot be correlated with any type of gastro-esophageal 
reflux.
16,17
Various hypotheses have been suggested to explain persistent 
symptoms in spite of adequate PPI treatment. Of them, esoph-
ageal hypersensitivity to persistent reflux (weakly acidic/alkaline 
or bile reflux) seems to be the most plausible underlying mecha-
nism at least in part of these patients.
5,18
Definition of Weakly Acidic Reflux
A recent consensus report provided a detailed nomenclature 
for reflux patterns detected by impedance pH monitoring.
19 An 
impedance detected reflux is defined as acid when the esophageal 
pH falls to ＜ 4, or when reflux occurs with the esophageal pH 
already < 4. When the esophageal pH falls by ≥ 1 unit, but re-
mains ＞ 4, it is considered “weakly acidic reflux.” The term 
“weakly alkaline reflux” is reserved for reflux episodes during 
which the esophageal pH increases to ＞ 7. An alternative clin-
ical classification prevalent in much of the literature considers 
acid (nadir pH ＜ 4), or non acid (nadir pH ＞ 4) reflux with 
non acid reflux further separated into weakly acidic (nadir pH 
4-7) or weakly alkaline (nadir pH ≥ 7).
20
Although commonly considered as synonym, duodenogas-
tro-esophageal reflux (DGER) and weakly acidic reflux are dif-
ferent type of events. Most DGER occurs in an acidic envi-
ronment.
Prevalence of Weakly Acidic Reflux in 
Refractory GERD
The prevalence of weakly acidic reflux in refractory GERD 
depends on the conditions considered to perform reflux 
monitoring. Although several weakly acidic reflux episodes can 
be detected during 24-hour impedance-pH monitoring per-
formed “off” PPI, this type of refluxate becomes particularly sig-
nificant during studies performed “on” PPI.
16,17,21,22 Vela et al
22 
used stationary impedance-pH monitoring to compare post-
prandial recordings of the same subject “on” and “off” PPI. The 
treatment provoked no reduction in the total number of reflux 
events, but there was a shift in the refluxate’s pH from acidic to 
weakly acidic. Heartburn was replaced by regurgitation, which 
became the predominant symptom in these patients. Studies in 
patients with refractory GERD showed that weakly acidic reflux 
could be associated with 30%-40% of symptoms.
16,17
For example, a study in 168 refractory GERD patients dem-
onstrated that 37% of patients had a positive association 
(symptom index [SI]) between symptoms and weakly acidic 
reflux. Typical GERD symptoms (particularly regurgitation) 
were more likely to be associated to weakly acidic reflux (42%), 
compared with atypical symptoms (22%).
16
Zerbib et al
17 observed a positive symptom-association be-
tween reflux and symptoms in 41 of 74 symptomatic patients 
(55%) who were not receiving PPI therapy and in 22 of 60 symp-
tomatic patients (37%) who were receiving PPI therapy. A tem-
poral relationship was established between symptoms and weakly 
acidic reflux in 4.1% and 16.7% of patients who were “off” and 
“on” PPI therapy, respectively.
In a recent retrospective review of 200 PPI refractory pa-
tients, it was found that 50% had only persistent weakly acidic re-
flux and the other 50% had mixed acid and weakly acidic reflux. 
More than half of these patients had a negative SI, suggesting 
functional heartburn rather than GERD.
23
Potential Mechanisms for Weakly Acidic 
Reflux-Related Symptoms
The mechanisms by which weakly acidic reflux can provoke 
persistence of symptoms in patients “on” PPI remain con-
troversial. It has been proposed: (1) esophageal distension by in-
creased reflux volume, (2) persistent impairment of esophageal Emmanouela Tsoukali and Daniel Sifrim
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mucosa due to weakly acidic reflux containing bile acids and (3) 
esophageal hypersensitivity to non-acid components of gastric 
contents.
The proximal extent of reflux can be used as an indirect or 
surrogate measure of reflux volume. It has been demonstrated 
that proximal extent of reflux is the most important determinant 
for reflux perception in patients with refractory GERD 
symptoms.
24,25 However, studies showed considerable overlap in 
the proximal extent of symptomatic and asymptomatic weakly 
acidic reflux events. Thus far, there is no evidence that weakly 
acidic reflux events have a particularly large volume.
Balloon distension and barostat studies have demonstrated 
that the proximal esophagus is more sensitive and less compliant 
than the distal part.
26-29 Mixed weakly acidic reflux events, con-
taining gas, might produce increased distension of the proximal 
esophagus. Recent studies confirm that the presence of gas in the 
refluxate increase the probability that a reflux event will be 
perceived.
18,25,30 These findings can explain why mixed - weakly 
acidic reflux episodes, reaching the proximal esophagus, are more 
likely to be symptomatic.
Patients with NERD have no macroscopic erosions but mu-
cosal biopsies can show several non specific changes including di-
lation of intercellular spaces. This finding has been proposed to 
be very important in the pathophysiology of symptoms in these 
patients. In human, intraesophageal perfusion with weakly acidic 
solutions containing bile salts can provoke heartburn.
31 In vitro 
studies can explain such finding. Exposure of rabbit esophageal 
mucosa to weakly acidic solutions containing bile acids (compara-
ble situation to patients “on” PPIs), increases mucosal perme-
ability and induces dilation of intracellular spaces.
32
Most patients whose symptoms are related to weakly acidic 
reflux do not have an increased number of reflux events, suggest-
ing esophageal hypersensitivity to less acidic refluxate.
33 Studies 
so far have evaluated the relationship between weakly acidic re-
flux and symptoms in refractory GERD patients. A comparison 
of this relationship with PPI success patients is warranted ie, a 
similar degree of weakly acidic reflux in both groups, will re-
inforce the idea of hypersensitivity to weakly acidic reflux in re-
fractory GERD.
14
The Role of Weakly Acidic Reflux in 
Respiratory Disorders
The role of weakly acidic reflux or aspiration of weakly acidic 
gastric components in respiratory disorders is still controversial. 
Many patients with respiratory disorders are taking PPIs to re-
duce gastric acid secretion. However, PPI treatment does not 
prevent patients from aspirating weakly acidic gastric juice. In a 
recent study, a positive association between cough and weakly 
acidic reflux has been identified in a subgroup of patients with 
unexplained chronic cough.
34 Symptom association analysis was 
performed using the symptom association probability (SAP).
35 
Overall, 36 of 100 patients showed a positive SAP (9 for acid re-
flux, 23 for weakly acidic reflux and 4 for both acid and weakly 
acidic reflux). The association between weakly acidic reflux and 
cough was observed in 15 of 77 patients “off” PPI and 8 of 23 pa-
tients “on” PPI. Reflux related-cough might be due to micro-as-
piration, vagal reflex originating from the distal esophagus and 
airway hypersensitivity.
36
Increased gastro-esophageal reflux is highly prevalent in pa-
tients with cystic fibrosis. In these patients, acid reflux is the most 
common, but weakly acidic reflux may also occur and provoke 
symptoms in these patients.
37 Finally, lung transplant patients 
usually receive PPI treatment. In these patients, aspiration is 
common, and pepsin and bile acids are frequently found in bron-
choalveolar lavage fluid in spite of the PPI therapy. One-half of 
the lung transplant patients have increased gastro-esophageal re-
flux, and weakly acidic reflux is particularly common in patients 
“on” PPI.
38 Moreover, bile acids in bronchoalveolar lavage fluid 
was more frequently observed in patients with nocturnal weakly 
acidic reflux.
The Role of Weakly Acidic Reflux in 
Mucosal Damage (Erosive Esophagitis and 
Barrett’s Esophagus)
The number of weakly acidic reflux episodes is not increased 
in patients with erosive esophagitis compared to patients with 
NERD and healthy controls.
30,39,40 These results suggest that 
weakly acidic reflux does not contribute significantly to esoph-
ageal mucosal damage.
30,41,21
Does weakly acidic reflux have a role in the pathogenesis of 
Barrett’s esophagus? A recent study assessed prevalence of acid 
and weakly acidic reflux in patients with short-segment Barrett’s 
esophagus. When patients were studied “off” PPI, the number of 
weakly acidic reflux events was normal. When the study was per-
formed “on” PPI, the majority of persistent reflux was weakly 
acidic. The authors speculated that pepsin and bile acids in weak-
ly acidic conditions could be relevant for Barrett’s transforma-
tion.
42 They suggested that proteolytic activity of pepsin is main-Weakly Acidic Reflux and PPI
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tained up to pH 5.5 and denaturation occurs at pH ＞ 7.
43 
Furthermore, bile acids can impair esophageal mucosal integrity 
also in a weakly acidic environment.
32 Therefore, the authors sug-
gested that regression of intestinal metaplasia with long-term PPI 
therapy would not be expected with persistence of weakly acidic 
containing bile acids, and in fact it has been reported that re-
gression can occur in only 30% of short-segment Barrett’s esoph-
agus patients.
44
The Role of DGER in PPI Failure
It should be emphasized that weakly acidic reflux and 
DGER are not synonyms. Only 10%-15% of weakly acidic reflux 
is considered to contain significant amount of bile. A recent study 
using simultaneous Bilitec and impedance monitoring showed no 
correlation between the percent time of bilirubin absorbance and 
weakly acidic reflux parameters.
45 To the contrary, the majority of 
bile reflux events occur concomitantly with acid reflux.
40,46,47
Koek et al
48 used combined ambulatory pH and bilirubin ab-
sorbance monitoring to assess patients with GERD who were 
“off” PPI therapy. In these patients, acid reflux rather than 
DGER was the main contributor to esophageal symptoms. The 
positive SAP for acid reflux, DGER and mixed reflux were 22%, 
7% and 10%, respectively.
However, when patients with persistent reflux symptoms de-
spite PPI therapy underwent combined ambulatory pH and bi-
lirubin absorbance monitoring, there was a higher prevalence of 
DGER (64%) than of acid reflux (37%).
21 PPI therapy reduces 
acid and bile reflux,
49,50 but persistent symptoms could be tempo-
rally associated with isolated bile reflux episodes.
51 Several stud-
ies
21,31,52 provided evidence for a potential contribution of bile 
acids in the generation of esophageal symptoms. In contrast, a re-
cent study by Gasiorowska et al
53 showed that there is no differ-
ence in the degree of DGER between patients who failed to re-
spond and those who achieved complete symptom resolution 
“on” PPI once daily. In this study, persistent symptoms in the 
PPI failure group were more commonly associated with acid re-
flux than with DGER.
Treatment of Weakly Acidic Reflux in 
Patients With Refractory GERD
Treatment strategies to reduce the number or effect of weakly 
acidic reflux could involve drugs that decrease transient lower 
esophageal sphincter relaxations (TLESRs) (ie, baclofen or sim-
ilar), improve oesophageal mucosa resistance or visceral pain 
modulators. Finally, anti-reflux surgery can be considered, only if 
a clear symptom-weakly acidic reflux association was demon-
strated.
Pharmacological Treatment
All currently used anti-reflux drugs induce a shift in the acid-
ity of the refluxate, whereas they do not decrease the total number 
of reflux episodes. Most acid and weakly acidic reflux events oc-
cur during TLESRs. Baclofen, a gamma-aminobutyric acid 
B-receptor agonist, was introduced into the clinical arena as a po-
tential add-on treatment for patients who failed PPI treatment 
(once or twice daily).
54,55 Baclofen reduces TLESR rate by 
40%-60%, reflux episodes by 43%, increases lower esophageal 
sphincter basal pressure, and accelerates gastric emptying.
54-56 
Baclofen has been shown to significantly reduce weakly acidic re-
flux and DGER, as well as DGER-related symptoms during 
PPI therapy.
57,58
Baclofen has central nervous system effects that limit its clin-
ical value for treating GERD. As the drug crosses the blood- 
brain barrier, a variety of central nervous system-related side ef-
fects may occur including somnolence, confusion, dizziness, 
lightheadedness, drowsiness, weakness and trembling. Baclofen 
has short pharmacological half-life (3-4 hours) and necessitates 
dosing three or more times per day.
Attention is now focussing on the development of new gam-
ma-aminobutyric acid B-receptor agonists that act primarily at 
peripheral sites and therefore have better tolerability. For exam-
ple, lesogaberan has a similar pharmacodynamic effect on reflux 
parameters to baclofen, resulting in almost complete inhibition of 
TLESRs in dogs
59 and a similar degree of inhibition as baclofen 
in healthy subjects and GERD patients.
60 In contrast to baclofen, 
however, this agent appears to act in the periphery, with very low 
incidence of central nervous system-related adverse effects mak-
ing it more interesting as an add-on therapy for the treatment of 
GERD patients with incomplete response to PPI therapy.
Until present there are no studies that specifically evaluated 
the value of visceral pain modulators in patients with refractory 
GERD. However, given the fact that most of the patients who 
fail PPI treatment originate from the non-erosive reflux disease 
group, and that up to 40% of the PPI failure subjects show a lack 
of either weak or acidic reflux during intra-esophageal impedance 
assessment, the usage of these agents is highly attractive.
16,61 Pain 
modulators such as tricyclic antidepressants, trazodone and               Emmanouela Tsoukali and Daniel Sifrim
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selective serotonin reuptake inhibitors have all been shown to im-
prove esophageal pain in patients with non-cardiac chest 
pain.
16,62,63 The pain modulators are used in non-mood-altering 
doses, and they presently provide a therapeutic alternative until 
more novel and esophageal-specific compounds are available.
So far, controlled pharmacological studies targeting weakly 
acidic reflux in patients with refractory GERD are unavailable.
Anti-reflux Surgery
A recent surgical study reported that refractory GERD was a 
very common (88%) indication for anti-reflux surgery.
64 Interest-
ingly, the most common preoperative symptom under failure of 
medical anti-reflux treatment was regurgitation (54%). Overall, 
82% of the patients reported that the preoperative reflux symp-
tom completely resolved, and 94% were satisfied with the results 
of the surgery. In another study that included only 30 subjects 
with refractory GERD, who were followed for a period of 12 
months, the main preoperative symptoms were regurgitation 
(93%) and heartburn (60%).
65 At the end of 1 year post surgery, 
all patients were completely relieved of heartburn, but only 86% 
reported resolution of regurgitation. Patient satisfaction rate with 
the surgery was 87%.
Two recent studies suggest that a positive SI during im-
pedance-pH monitoring in patients “on” PPIs can predict a fa-
vorable response to medical or surgical therapy. The first study 
by Mainie et al
66 followed 19 patients who were refractory to a 
double-dose of PPI and successfully underwent laparoscopic 
Nissen fundoplication. Prior to surgery, 18 of the 19 patients 
were found to have a positive SI on esophageal impedance-pH 
monitoring. After a mean follow-up of 14 months, 16 of the pa-
tients with a positive SI were asymptomatic. The second study by 
Becker et al
67 assessed 56 patients with persistent symptoms on a 
single dose of PPI and abnormal impedance-pH monitoring. 
Most of these patients had a positive SI and later demonstrated 
significantly better response to doubling the PPI dose as com-
pared to subjects with normal impedance pH monitoring. Both 
of the aforementioned studies were uncontrolled and did not 
clearly describe whether symptoms were due to weakly acidic re-
flux or remaining acid reflux, which could have been detected by 
a simple pH test and potentially treated with higher-dose PPI. 
Finally, anti-reflux surgery should be considered, only if a clear 
symptom-weakly acidic reflux association was demonstrated.
Conclusion
Management of PPI failure patients remains a challenge. 
There is a significant overlap of refractory GERD with other dis-
orders, therefore the diagnosis of GERD should always be recon-
sidered in patients with persistent symptoms despite PPI therapy. 
In addition, a precise definition of PPI failure and PPI success is 
needed.
Weakly acidic reflux has been proposed to be one of the un-
derlying mechanisms of refractory GERD. To establish a defi-
nite role of weakly acidic reflux in refractory GERD, studies 
comparing the impact of weakly acidic reflux in patients with PPI 
failure vs PPI success are lacking and, even more important, we 
are still waiting for positive controlled outcome studies targeting 
this type of reflux.
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